Post-injection acute lower back discomfort has been added to the list of potential side effects associated with intralesional therapy for Peyronie’s disease after it was noted in a study with collagenase Clostridium histolyticum.
Researchers need to find out the frequency or what caused it. They analyzed a large cohort to determine the frequency of this adverse occurrence and any temporal connections. From October 2015 through December 2020, they looked back at information from all males who had collagenase injections for Peyronie’s disease at their facility. A total of 330 participants were enrolled in the trial, and 300 completed at least 1 full session (8 injections).
The frequency and duration of back pain and its connections to socioeconomic status and co-morbidities were among the outcomes that were tracked. The results showed that 19 patients (5.8%) out of 330 had at least 1 episode of acute lower back discomfort after receiving an injection. Only 4 people (1.3% of the total) experienced back pain after receiving all 8 injections in the course of treatment for 300 who received at least 1 full course of injections. Iterations were made on a selected subset (16 or 24 injections). In the 2nd round, 8.7% (13/149) of people reported back pain, and in the 3rd round, 6.9% (3/43). There was no correlation discovered between these factors and age, diabetes, or a prior history of back discomfort. Most incidents happened quickly after the injection, and all resolved with a single dosage of ketorolac.
This retrospective, a single-center study, found that up to 6% of patients who received intralesional collagenase injections for Peyronie’s disease experienced acute lower back pain. Counseling patients about this danger may help. Additional treatment cycles increase the incidence rate. There is a lack of prospective safety data for more than 8 injection doses. Chronic back pain was not a problem for any of the patients.